Lucid Diagnostics Inc <LUCD.OQ> expected to post a loss of 12 cents a share - Earnings Preview
Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to show a rise in quarterly revenue when it reports results on August 13 for the period ending June 30 2025
The New York City-based company is expected to report a 17.0% increase in revenue to $1.142 million from $976 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lucid Diagnostics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00, about 66.8% above its last closing price of $1.00
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.16 | -0.16 | -0.52 | Missed | -228.7 |
Dec. 31 2025 | -0.19 | -0.18 | Beat | 5.3 | |
Sep. 30 2024 | -0.22 | -0.22 | -0.25 | Missed | -13.6 |
Jun. 30 2024 | -0.22 | -0.22 | -0.23 | Missed | -4.5 |
Mar. 31 2024 | -0.26 | -0.27 | -0.40 | Missed | -49.3 |
Dec. 31 2023 | -0.27 | -0.26 | -0.25 | Beat | 3 |
Sep. 30 2023 | -0.27 | -0.27 | -0.34 | Missed | -24.8 |
Jun. 30 2023 | -0.32 | -0.32 | -0.23 | Beat | 28.3 |
This summary was machine generated August 11 at 13:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
